India & United States — National Institutes of Health

India: India is experiencing a sharp rise in PMOS diagnoses, especially among urban adolescents and young women, making the name change particularly important for improving awareness and management.

United States — National Institutes of Health: The United States — National Institutes of Health is mentioned as a potential source for increased research funding for Polyendocrine metabolic ovarian syndrome, particularly in areas like diabetes and heart disease, due to the new name's broader scope.

India: India>>> has confirmed the safety of its two nationals on the MV Hondius and its medical experts have reassured the public that there is no pandemic threat to the country.

United States — National Institutes of Health: The United States — National Institutes of Health>>>'s decision to end funding for global infectious disease research networks has drawn criticism amid ongoing outbreaks.

India: India, along with the African Union, postponed the India-Africa Forum Summit due to the evolving health situation in parts of Africa, demonstrating the international repercussions of the Ebola outbreak.

United States — National Institutes of Health: The United States — National Institutes of Health supported a 2018 animal study that demonstrated the efficacy of the BDBV289-N antibody candidate against the Bundibugyo strain.

India: India is a country where Medicenna Therapeutics has granted patents and pending applications, extending its intellectual property reach.

United States — National Institutes of Health: The United States — National Institutes of Health is a co-owner of one of the newly issued US patents, indicating its collaboration with Medicenna Therapeutics on IL-4 Superkine fusion proteins.